Comparative analysis of access to patented HIV/AIDS pharmaceutical medicines through the Canadian and EU TRIPS flexibilities measures: are they efficacious or overly burdensome and ineffective measures?
DOI:
https://doi.org/10.17159/1727-3781/2012/v15i2a2498Keywords:
HIV/AIDS, pharaceuticals, patents TRIPS, Canada, EUAbstract
This paper evaluates the Canadian and the European Union's (EU) implementation of the World Trade Organisation (WTO) General Council Decision of 2003, which resolved that developed nations could export patented pharmaceutical drugs to member states in order to address public health challenges such as Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), tuberculosis, malaria and other epidemics, such states including Sub-Saharan Africa (SSA). The author makes a primarily textual appraisal of how and to what extent the Canada Access to Medicine Regime (CAMR) and European Union (EU) Regulations benefit, for instance, SSA countries in the WTO in their quest to make essential medicine more accessible. The author argues that although there are identifiable complexities inherent in the Canadian and the EU's access to pharmaceutical product regimes, there are far more important incentives and benefits that can be reaped in taking advantage of the respective systems. The author recommends that countries facing public health crises/emergencies, such as SSA countries, and non-governmental organisations (NGOs) take advantage of the regulatory flexibilities of Canada and the EU in their efforts to provide their communities with essential HIV/AIDS treatment, and treatment for other diseases such as malaria. The author dismisses the arguments against TRIPS (Trade-Related Aspects of Intellectual Property) flexibilities-inspired legislation and similar measures as mostly mere rhetoric and hair-splitting, because they sometimes unwarrantedly dismiss a workable solution to public-health problems.
Downloads
References
Bibliography
Amollo 2009 AJICL
Amollo R “Revisiting the Trips Regime: Rwanda-Canadian ARV Drug Deal ‘Tests’ the WTO General Council Decision” 2009 African Journal of International and Comparative Law 240-269
Bhattacharya 2008 Va J Int'l L
Bhattacharya R "Are Developing Countries Going Too Far on TRIPS? A Closer Look at the New Laws in India" 2008 Va J Int'l L 395-421
Bluestone 2001 Tropical Medicine and International Health
Bluestone K "Safeguarding Developing Countries' Rights to Affordable Medicines for HIV/AIDS: How Effective are International Trade Rules?" 2001 Tropical Medicine and International Health 161-162
Chirwa 2003 SAJHR
Chirwa DM "The Right to Health in International Law: Its Implications for the Obligations of State and Non-state Actors in Ensuring Access to Essential Medicine" 2003 South African Journal of Human Rights 541-566
Collins 2001 Syracuse J Int'l L
Collins J "The Pharmaceutical Companies Versus AIDS Victims: A Classic Case of Bad Versus Good? A Look at the Struggle between Intellectual Property Rights and Access to Treatment" 2001 Syracuse J Int'l L 159-183
Cornides 2007 JWIP
Cornides J "European Union Adopts Regulation on Compulsory Licensing of Pharmaceutical Products for Exports" 2007 JWIP 70-77
El-Said 2007 JWIP
El-Said M "TRIPS-Plus Implications for Access to Medicines in Developing Countries: Lessons from Jordan-United States Free Trade Agreement" 2007 JWIP 438-475
Gumedze 2004 AJHR
Gumedze S "HIV/AIDS and Human rights: The role of the African Commission on Human and Peoples' Rights" 2004 AJHR 181-200
Hassim, Heywood and Berger Health and Democracy
Hassim A, Heywood M and Berger J Health and Democracy: A Guide to Human Rights, Health Law and Policy in Post-Apartheid South Africa (Siberink Cape Town 2007)
Heyns and Killander Key Human Rights Documents
Heyns C and Killander M Compendium of Key Human Rights Documents of the African Union 3rd ed (Pretoria University Press Pretoria 2007)
Keiser et al 2004 American Journal of Tropical Medicine and Hygiene
Keiser J, Utzinger J, Caldas de Castro M, Smith T.A, Tanner M, and Singer B.H "Urbanization in Sub-Saharan Africa and Implications for Malaria Control" 2004 American Journal of Tropical Medicine and Hygiene 118-127
Kirby 2004 AJHR
Kirby M "The Never-ending Paradoxes of HIV/AIDS and Human Rights" 2004 AJHR 163-180
Lindstrom 2010 International Law and Politics
Lindstrom B "Scalling Back TRIP-Plus: An Analysis of Intellectual Property Provisions in Trade Agreements and Implications" 2010 International Law and Politics 917-980
Ng and Kohler 2008 Health Law Journal
Ng E and Kohler J "Finding Flaws: The Limitations of Compulsory Licensing for Improving Access to Medicines" 2008 Health Law Journal 143-172
Ngwena 2002 SAPL
Ngwena C "AIDS in Africa: Access to Health Care as a Human Right" 2002 SAPL 1-21
Sasjack 2008 AJLM
Sasjack S "Demanding Individually Safe Drugs Today: Overcoming the Cross-labelling Legal Hurdle to Pharmacogenomics" 2008 AJLM 7-40
Savoie 2007 Va J Int'l L
Savoie B "Thailand's Test: Compulsory Licensing in an Era of Epidemiologic Transition" 2007 Va J Int'l L 211-248
Sibanda 2009 Acta Academica
Sibanda O "Parallel importation and compulsory licensing in Kenya and South Africa as measures to access HIV/AIDS medicine" 2009 Acta Academica 183-206
Singh, Govender and Reddy 2005 Georgetown Journal on Poverty Law & Policy
Singh JA, Govender M and Reddy N "South Africa a Decade after Apartheid: Realising Health through Human Rights" 2005 Georgetown Journal on Poverty Law & Policy 355-388
Tsoose 2010 PELJ
Tsoose CI "The Impact of HIV/AIDS Regarding Informal Social Security: Issues and Perspectives from a South African Context" 2010 PELJ 407-447
Register of government documents
Canada
Standing Committee on Industry, Science and Technology, 37th Parl 3d session, No. 004 (26 February 2004)
Register of international instruments
Decision on LDC members' Obligation under Article 70.9 of TRIPS (2002)
Decision on LDC members' Obligation under Article 70.9 of the TRIPS Agreement with Respect to Pharmaceutical Products of 8 July 2002
Decision on TRIPS Extension (2002)
Decision on the Extension of the Transition Period under Article 66.1 of the TRIPS Agreement for LDC Members for Certain Obligations with Respect to Pharmaceutical Products of 27 June 2002
Doha Decision on Paragraph 17 of TRIPS (2001)
Decision on Paragraph 17 of the Main Doha Declaration of 14 November 2001
Doha Declaration on TRIPS (2001)
WTO 2001. Declaration on the TRIPS Agreement and Public Health. Doc WT/MIN(01)/DEC/2 92001
Hong Kong Ministerial Declaration on TRIPS (2005)
Hong Kong Ministerial Declaration on TRIPS and Public Health (2005)
TRIPS Amendment (2005)
WTO 2005. Amendment to the TRIPS Agreement: Decision of 6 December 2005. Doc – WT/L/641 - 8 December 2005
TRIPS Agreement (1994)
WTO 1994. Annex 1C of the WTO Agreement: The Agreement on Trade-Related Aspects of Intellectual Property. U.N.T.S 1869 reprinted in International Legal Materials 33:81
Register of legislation
Canada
Act to amend the Patent Act and the Food and Drugs Act - The Jean Chrétien Pledge to Africa, S.C. 2004, c. 23
Patent Act, R.S.C. 1985
United States
Best Pharmaceuticals for Children Act of 2002, Public Law (P.L.) 107-109
Food and Drug Administration Modernization and Accountability Act of 1997
South Africa
Constitution of the Republic of South Africa, 1996
Consumer Protection Act 68 of 2008
Medicines and Related Substances Control Amendment Act 90 of 1997
Register of case law
Allpass v Mooikloof Estates (Pty) Ltd t/a Mooikloof Equestrain Centre 2011 ZALC 2
Bootes v Eagle Inc System KZ Natal (Pty) Ltd 2008 29 ILJ 139
EN v Government of South Africa 2007 1 All SA 74 (D)
Government of the Republic of South Africa v Grootboom 2001 1 SA 46 (CC)
Hoffmann v South African Airways 2000 ZACC 17
Minister of Health v TAC (No 2) 2002 5 SA 721 (CC)
Pharmaceutical Manufacturers' Association and v the President of the Republic of South Africa Case no 4183/98
Register of internet sources
Apotex 2008 www.apotex.com
Apotex 2008 Canadian Company Receives Final Tender Approval From Rwanda For Vital AIDS Drug www.apotex.com/global/about/press/
asp (date of use 25 February 2011)
AU 2003 www.iss.co.za
African Union 2003 Maputo Declaration on Malaria, HIV/AIDS, Tuberculosis and Other Related Infectious Diseases. Assembly, Second Ordinary Session, 1-0 – 12 July 2003, Maputo Mozambique www.iss.co.za/AF/RegOrg/
unity_to_union/pdfs/au/assembly/moz03decl.pdf (date of use 6 December 2011)
Bubela and Morin 2010 dev.ulb.ac.be
Bubela T and Morin J 2010 Lost in Translation: The Canadian Access to Medicine from Transnational Activism to Domestic Implementation dev.ulb.ac.be/sciencespo/dossiers_membres/morin-jean-frederic/fichiers/morin-jean-frederic-publication71.pdf (date of use 6 December 2011)
Cohen-Kohler, Esmail and Cosio 2007 www.globalizationandhealth.com
Cohen-Kohler JC, Esmail LC and Cosio AP 2007 "Canada's Implementation of the Paragraph 6 Decision: Is it Sustainable Public Policy?" 2007 Globalization and Health www.globalizationandhealth.com/content/3/1/12 (date of use 12 January 2010)
Competition Commission 2004 www.compcom.co.za
Competition Commission 2004 Towards a free and fair economy for all: GSK and BI issue anti-retroviral licences www.compcom.co.za/assets/Uploads/
AttachedFiles/MyDocuments/March-04-Newsletter.pdf (date of use 19 December 2011)
CIPR 2002 www.iprcommission.org
Commission on Intellectual Property Rights 2002 Integrating Intellectual Property Rights and Development Policy www.iprcommission.org/papers
/pdfs/final_report/CIPRfullfinal.pdf (date of use 6 December 2011)
EU 2006 www.cptech.org
European Union 2006 Regulation (EC) No 816/2006 of the European Parliament and the Council of 17 May 2006, Official Journal of European Union L157 www.cptech.org/ip/wto/p6/eu-cl06.pdf (date of use 5 February 2011)
EU 2004 ec.europa.eu
European Union 2004 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Official Journal of the European Union ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol1/
reg_2004_726/reg_2004_726_en.pdf (date of use 7 January 2010)
European Commission 2009 ec.europa.eu
European Commission 2009 Communication from the Commission: Executive Summary of the Pharmaceutical Sector Inquiry Report ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication_en.pdf (date of use 7 January 2010)
Froneman 2000 www.panos.org.ukss
Froneman M 2000 Beyond Our Means: The Cost of Treating HIV/AIDS in the Developing World www.panos.org.ukss (date of use 17 June 2009)
Hestermeyer 2007 www.asil.org
Hestermeyer HP 2007 "Canadian-made Drugs for Rwanda: The First Application of the WTO Waiver on Patents and Medicines" 2007 American Society of International Law www.asil.org/insights071210.cfm (date of use 9 January 2011)
Human Rights Working Group 2007 www.camr-rcam.gc.ca
Human Rights Working Group on HIV/AIDS and Public Health: McGill University 2007 Canada's Access to Medicines Regime (CAMR) Consultation Submission (24 January 2007) www.camr-rcam.gc.ca/review-reviser/camr_rcam_mcgill_20-eng.pdf (date of use 10 November 2010)
Li 2008 www.wider.unu.edu
Li X 2008 The Impact of Higher Patent Protection for Pharmaceutical Industries under the TRIPS Agreement – A Comparative Study of China and India, United Nations University Research Paper No 2008 www.wider.unu.edu/publications/working-papers/research-papers/2008/en_GB/rp2008-36/ (date of use 10 November 2010)
Love 2007 keionline.org
Love JP 2007 "Some Recent Examples of the Use of Compulsory Licenses on Patent" 2007 Knowledge Ecology International keionline.org/content/view/90/misc-docs/recent_cls_8mar07.pdf (date of use 10 November 2010)
Masungu, Villanueva and Blasetti 2004 www.ipsonline.org.resource.docs
Masungu SF, Villanueva S and Blasetti R 2004 Utilizing TRIPS Flexibilities for Public Health Protection through South–South Regional Framework www.ipsonline.org.resource.docs/trip-health-southcentre.2004.pdf (date of use 15 December 2011)
Medicins Sans Frontiers 2006 www.msf.ca
Medicins Sans Frontiers 2006 Neither Expeditious, Nor a Solution: The WTO August 30 Decision is Unworkable www.msf.ca/aids2006/files/
REP_JCPA_en.pdf (date of use 15 December 2011)
Saggi 2007 www.iprsonline.org
Saggi K 2007 Trade-Related Policy Coherence and Access to Essential Medicine www.iprsonline.org/ictsd/docs/Saggi%20%20Working%20-Paper.pdf (date of use 5 December 2011)
SALC 2011 www.unaids.org.cn
South African Litigation Center 2011 Litigation Manual Series Equal Rights for All: Litigating Cases of HIV-related Discrimination www.unaids.org.cn/pics/20111103122528.pdf (date of use 6 December 2011)
Schoofs 1999 www.village
Schoofs M 1999 AIDS, the Agony of Africa: Ending the Epidemic www.village (date of use 13 January 2011)
Statistics South Africa 2010 www.statssa.gov.za
Statistics South Africa 2010 Mid-year Population Estimates www.statssa.gov.za/publications/P0302/P03022010.pdf (date of use 5 December 2011)
UN 2001 www.who.int
United Nations 2001 Declaration of Commitment on HIV/AIDS, United Nations General Assembly Special Session on HIV, 25-27 June 2001 www.who.int/hiv/pub/advocacy/aidsdeclaration_en.pdf (date of use 5 December 2011)
UNESCO-IIEP 2002 www.unesco.org.iiep
UNESCO-IIEP 2002 The Impact of HIV/AIDS on Education and Institutionalizing Preventive Education www.unesco.org.iiep (date of use 15 November 2010)
United States Federal Drug Administration Date Unknown www.fda.gov
United States Federal Drug Administration Date Unknown Electronic Orange Book – Approved Drug Products with Therapeutic Equivalents www.fda.gov (date of use 18 December 2010)
WHO 2007 whqlibdoc.who.int
World Health Organisation 2007 Model List for Essential Medicines, 15th List, March 2007 whqlibdoc.who.int (date of use 5 January 2011)
WTO 2011 wto.org
World Trade Organisation 2011 Protocol Amending the TRIPS Agreement Status of Acceptance, IP/C/W/490/Rev.8, 6 October 2011 wto.org/english/tratop_e/trips_e/ta_docs (date of use 29 November 2011)
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Omphemetse S Sibanda
This work is licensed under a Creative Commons Attribution 4.0 International License.
.png){kind=spacer}